Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Jun. 30, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Dr. George Magrath [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On June 5, 2026, Dr. George Magrath, the Company’s Chief Executive Officer, adopted a Rule 10b5‑1 trading plan (as defined in Rule 10b5‑1(c) under the Securities Exchange Act of 1934) providing for the potential sale of up to 1,053,586 shares of the Company’s common stock. Pursuant to the trading plan, sales of shares may commence on or after September 4, 2026, and are scheduled to terminate on or prior to September 25, 2028, subject to earlier termination in accordance with its terms.
|
| Name | Dr. George Magrath |
| Title | Chief Executive Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | June 5, 2026 |
| Expiration Date | September 25, 2028 |
| Arrangement Duration | 752 days |
| Aggregate Available | 1,053,586 |
| Rob Gagnon [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On April 30, 2026, Rob Gagnon, the Company’s Chief Financial Officer, adopted a Rule 10b5‑1 trading plan (as defined in Rule 10b5‑1(c) under the Securities Exchange Act of 1934) providing for the potential sale of up to 536,589 shares of the Company’s common stock. Pursuant to the trading plan, sales of shares may commence on or after August 10, 2026, and are scheduled to terminate on or prior to August 28, 2028, subject to earlier termination in accordance with its terms.
|
| Name | Rob Gagnon |
| Title | Chief Financial Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | April 30, 2026 |
| Expiration Date | August 28, 2028 |
| Arrangement Duration | 749 days |
| Aggregate Available | 536,589 |
| Dr. Sally Tucker [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On May 1, 2026, Dr. Sally Tucker, the Company’s Chief Medical Officer, adopted a Rule 10b5‑1 trading plan (as defined in Rule 10b5‑1(c) under the Securities Exchange Act of 1934) providing for the potential sale of up to 232,869 shares of the Company’s common stock. Pursuant to the trading plan, sales of shares may commence on or after June 1, 2026, and are scheduled to terminate on or prior to May 31, 2028, subject to earlier termination in accordance with its terms.
|
| Name | Dr. Sally Tucker |
| Title | Chief Medical Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | May 1, 2026 |
| Expiration Date | May 31, 2028 |
| Arrangement Duration | 730 days |
| Aggregate Available | 232,869 |